137 related articles for article (PubMed ID: 28472350)
1. Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices.
Perez Botero J; Majerus JA; Strege AK; Johnson RD; Chen D; Pruthi RK
Am J Clin Pathol; 2017 Jun; 147(6):604-610. PubMed ID: 28472350
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden.
Murphy CH; Sabath DE
Am J Clin Pathol; 2019 Feb; 151(3):302-305. PubMed ID: 30423028
[TBL] [Abstract][Full Text] [Related]
3. Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee.
Moore GW; Castoldi E; Teruya J; Morishita E; Adcock DM
J Thromb Haemost; 2023 Jan; 21(1):164-174. PubMed ID: 36695379
[TBL] [Abstract][Full Text] [Related]
4. The association between activated protein C ratio and Factor V Leiden are gender-dependent.
Hansen RS; Nybo M
Clin Chem Lab Med; 2019 Jul; 57(8):1229-1234. PubMed ID: 30903752
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
6. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Favaloro EJ; Orsag I; Bukuya M; McDonald D
Pathology; 2002 Aug; 34(4):348-55. PubMed ID: 12190294
[TBL] [Abstract][Full Text] [Related]
7. The response to activated protein C after cardiopulmonary bypass: impact of factor V leiden.
Donahue BS
Anesth Analg; 2004 Dec; 99(6):1598-1603. PubMed ID: 15562039
[TBL] [Abstract][Full Text] [Related]
8. [APC resistance--most frequent familial thrombophilia].
Herren S; Lämmle B
Ther Umsch; 1999 Sep; 56(9):499-501. PubMed ID: 10517118
[TBL] [Abstract][Full Text] [Related]
9. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of thrombophilia]].
Kemkes-Matthes B
Zentralbl Chir; 2001 Jun; 126(6):433-7. PubMed ID: 11446062
[TBL] [Abstract][Full Text] [Related]
11. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
Schöni R; Quehenberger P; Wu JR; Wilmer M
Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Maryamchik E; Rosenbaum MW; Van Cott EM
Arch Pathol Lab Med; 2018 Jan; 142(1):70-74. PubMed ID: 28920711
[TBL] [Abstract][Full Text] [Related]
14. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Kopytek M; Ząbczyk M; Malinowski KP; Undas A; Natorska J
Clin Chem Lab Med; 2020 Feb; 58(3):430-437. PubMed ID: 31539350
[TBL] [Abstract][Full Text] [Related]
15. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
Jadaon MM; Dashti AA; Lewis HL
Diagn Mol Pathol; 2010 Sep; 19(3):180-3. PubMed ID: 20736749
[TBL] [Abstract][Full Text] [Related]
17. Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene "Mutation" (G20210A).
Favaloro EJ
Semin Thromb Hemost; 2019 Oct; 45(7):730-742. PubMed ID: 31398733
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.
Mikovic D; Rakicevic L; Kovac M; Radojkovic D
Thromb Haemost; 2000 Oct; 84(4):723-4. PubMed ID: 11057877
[No Abstract] [Full Text] [Related]
19. Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods.
Maryamchik E; Van Cott EM
Arch Pathol Lab Med; 2020 Nov; 144(11):1401-1407. PubMed ID: 32101451
[TBL] [Abstract][Full Text] [Related]
20. Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Lindqvist PG; Svensson P; Dahlbäck B
J Thromb Haemost; 2006 Feb; 4(2):361-6. PubMed ID: 16420566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]